
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer
The FDA has granted priority review to a biologics license application (BLA) seeking the approval of sonesitatug vedotin (Sone-Ve; CMG901; AZD0901) for the second-line or later treatment of patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, or esophageal adenocarcinoma with Claudin 18.2 (CLDN18.2) expression on at least 25% of tumor cells at any staining intensity.1
The target action date under the Prescription Drug User Fee Act is anticipated to occur in the second quarter of 2027, per AstraZeneca.
The BLA was supported by
OS in the third- or later-line population served as the trial’s other dual primary end point, and patients treated with Sone-Ve at 2.2 mg/kg (n = 178) experienced a median OS of 10.0 months (95% CI, 7.2-11.4) vs 5.0 months (95% CI, 4.2-6.4) for investigator’s choice of therapy (n = 177; HR, 0.47; 95% CI, 0.36-0.62; P < .000001).
“After progressing on first-line treatment, patients with CLDN18.2-positive advanced gastric cancer have no targeted options. Sone-Ve is the first antibody-drug conjugate [ADC] targeting CLDN8.2 to improve OS for patients compared [with] current standard of care in this setting and across a population that encompasses a much broader definition of CLDN18.2 positivity than for current drugs,” Susan Galbraith, executive vice president of Oncology Hematology Research and Development at AstraZeneca, stated in a news release.1 “This priority review of our submission speaks to the significant potential of this medicine and accelerates the ability to bring forward a new targeted approach and alternative to traditional chemotherapy for thousands of patients in the United States."
What is the mechanism of action of Sone-Ve, and how was it investigated in CLARITY-Gastric01?
Sone-Ve is an investigational ADC in which a monoclonal antibody targeting CLDN18.2 is attached to the cytotoxic agent monomethyl auristatin E (MMAE) via a cleavable linker.2 CLDN18.2 is expressed in approximately 40% to 80% of gastroesophageal carcinomas, with that approximation varying based on the level of expression assessed.
CLARITY-GASTRIC01 was a global, open-label, randomized, sponsor-blinded trial that enrolled adult patients (n = 594) with second- or later-line unresectable, locally advanced or metastatic gastroesophageal carcinoma who expressed CLDN18.2 on at least 25% of tumor cells at any intensity of membranous staining.
In the dose-selection stage, patients were randomly assigned 1:1:1 to intravenous Sone-Ve at 2.2 mg/kg once every 3 weeks (n = 267); Sone-Ve at 1.8 mg/kg every 3 weeks (n = 62); or investigator's choice of therapy (n = 265). Notably, the 1.8-mg/kg arm was closed to enrollment, and the protocol was amended to a 1:1 randomization between the 2.8-mg/kg arm and the control arm. In the control arm, investigator’s choice of therapy for patients being treated in the second line included ramucirumab (Cyramza) plus paclitaxel, or paclitaxel or docetaxel alone for patients with a contraindication to ramucirumab. For patients treated in the third line or later, investigator’s choice of therapy comprised irinotecan, trifluridine/tipiracil (Lonsurf) in any sites outside of China, or apatinib (Aitan) for sites in China.
The dual primary end points were PFS by central review in the ITT population and OS in patients receiving treatment in the third line or later.
What safety findings were reported?
Safety data demonstrated that any-grade adverse effects (AEs) occurred in 97.3% of patients treated with Sone-Ve at 2.2 mg/kg ( n = 261) vs 94.0% of those in the investigator’s choice arm (n = 252). The respective rates of any-grade AEs possibly related to treatment were 85.8% and 81.3%. Serious AEs were experienced by 34.9% and 31.3% of patients, respectively.
For Sone-Ve, AEs led to treatment discontinuation, treatment interuption/dose dely, and dose reduction in 5.0%, 36.4%, and 21.1% of patients, respectively. These respective rates in the control arm were 4.4%, 40.5%, and 23.0%. AEs led to death in 4.2% of patients in Sone-Ve arm vs 2.4% of patients in the control arm; the respective rates of AEs leading to death that were possibly treatment-related were 1.1% and 0.8%.
References
- Sonesitatug vedotin granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers. News release. AstraZeneca. November 19, 2026. Accessed November 19, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/sonesitatug-vedotin-granted-priority-review-us-for-2nd-later-line-treatment-patients-with-cldn182-positive-advanced-gastric-gej-cancers.html
- Xu RH, Janjigian Y, Chen MH, et al. CLARITY-Gastric01: a phase 3 study of sonesitatug vedotin (Sone-Ve, AZD0901) in second or later-line advanced or metastatic Claudin 18.2-positive gastroesophageal carcinoma. Presented at: 2026 ESMO Congress; October 23-27, 2026; Madrid, Spain. Abstract LBA7.
Related to this article







